Skip to Content

DICOBALT EDETATE INJECTION 300MG

Active substance(s): DICOBALT EDETATE / DICOBALT EDETATE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1

NAME OF THE MEDICINAL PRODUCT
Dicobalt Edetate Injection 300mg

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ampoule contains 300mg Dicobalt Edetate INN (15mg/ml)

3

PHARMACEUTICAL FORM
Solution for Injection

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Dicobalt Edetate Injection is a specific antidote for acute cyanide poisoning. In
view of the difficulty of certain diagnosis in emergency situations, it is
recommended that Dicobalt Edetate Injection only be given when the patient is
tending to lose or has lost consciousness. The product should not be used as a
precautionary measure.

4.2

Posology and method of administration
Cyanide poisoning must be treated as quickly as possible and intensive
supportive measures must be instituted: clear airways and adequate ventilation
are essential. 100% oxygen should be administered concurrently with Dicobalt
Edetate.
Expert advice on the treatment of poisoning is available at the local poisons
centre.
Adults
One 300mg ampoule intravenously over approximately one minute. If the
patient shows inadequate response, a second ampoule may be given. If there is
no response after a further five minutes, a third ampoule maybe administered.

Each ampoule of Dicobalt Edetate Injection may be followed immediately by
50ml Glucose Intravenous Infusion BP 500g/l.
When the patient’s condition is less severe but in the physician’s judgement
still warrants the use of Dicobalt Edetate Injection, the period over which the
injection is given should be extended to 5 minutes.
Children
There is no clinical experience of the use of Dicobalt Edetate Injection in
children. As with adults the dose required will be related to the quantity of
cyanide ingested.
The elderly
There is no clinical evidence of the use of Dicobalt Edetate Injection in the
elderly, but there is no reason to believe that the dosage schedule should be
different from that for adults.

4.3

Contraindications
None

4.4

Special warnings and precautions for use
There is a reciprocal antidote action between cyanide and cobalt. Thus in the
absence of cyanide, Dicobalt Edetate Injection itself is toxic. It is therefore
essential that the product only be used in cases of cyanide poisoning. When
the patient is fully conscious, it is unlikely that the extent of poisoning
warrants the use of Dicobalt Edetate Injection.

4.5

Interaction with other medicinal products and other forms of interaction
No information is available

4.6

Pregnancy and lactation
No information is available

4.7

Effects on ability to drive and use machines
Not applicable

4.8

Undesirable effects
The initial effects of Dicobalt Edetate Injection are vomiting, a fall in blood
pressure and compensatory tachycardia. After this the patient should recover.

4.9

Overdose
Signs and symptoms - these may be due to cobalt toxicity or to an
anaphylactic type reaction, which may be dramatic. Oedema (particularly of
the face and neck), vomiting, chest pain, sweating, hypotension, cardiac
irregularities and rashes may occur.
Treatment - intensive supportive therapy is required.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Cyanide blocks intracellular respiration by binding to cytochrome oxidase.
Dicobalt Edetate Injection forms a stable complex with the cyanide thereby
acting as an antidote.

5.2

Pharmacokinetic properties
Only very limited data are available. Intravenous infusion of Dicobalt Edetate
Injection is likely to result in rapid distribution in the extracellular fluid
compartment. Excretion is entirely via the kidneys within 24 hours and it is
not metabolised.

5.3

Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are
additional to that already included in other sections of the SPC.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Dextrose Monohydrate
Water for Injections

6.2

Incompatibilities
Not applicable

6.3

Shelf life
Three years

6.4

Special precautions for storage
Store below 25°C away from light

6.5

Nature and contents of container
Packs of six Ph.Eur Type I glass ampoules each containing 20ml of rose-violet
coloured sterile pyrogen free solution

6.6

Special precautions for disposal
None

7

MARKETING AUTHORISATION HOLDER

SERB, 40 avenue George V, F-75008 PARIS, FRANCE

8

MARKETING AUTHORISATION NUMBER(S)
PL 26080/0001

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
31/05/1996

10

/

17/03/2003

DATE OF REVISION OF THE TEXT
20/11/2012

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide